Back to top
more

Idera Pharmaceuticals, Inc. (IDRA)

(Delayed Data from NSDQ)

$3.57 USD

3.57
1,700,174

+0.51 (16.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.56 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Are Options Traders Betting on a Big Move in Idera Pharmaceuticals (IDRA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Idera Pharmaceuticals (IDRA) stock based on the movements in the options market lately.

Idera Pharmaceuticals (IDRA) in Focus: Stock Moves 9.4% Higher

by Zacks Equity Research

Idera Pharmaceuticals (IDRA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Idera Completes Recruitment in Late-Stage Melanoma Study

by Zacks Equity Research

Idera (IDRA) closes enrollment in the late-stage ILLUMINATE-301 study, evaluating the combo of tilsotolimod plus Yervoy in patients with anti-PD-1 refractory advanced melanoma.

Axovant's GM1 Gangliosidosis Candidate Gets Orphan Drug Tag

by Zacks Equity Research

The FDA grants Orphan Drug status to Axovant's (AXGT) gene therapy candidate, AXO-AAV-GM1, being developed for the treatment of GM1 gangliosidosis. Shares decline despite the positive news.

Idera Pharmaceuticals (IDRA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Idera (IDRA) delivered earnings and revenue surprises of 7.14% and 1348.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Idera Pharmaceuticals (IDRA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Idera Pharmaceuticals, Inc. (IDRA) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Idera Pharmaceuticals, Inc. (IDRA).

Idera Pharmaceuticals (IDRA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Idera (IDRA) delivered earnings and revenue surprises of 13.04% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Idera Pharmaceuticals (IDRA) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Idera Pharmaceuticals (IDRA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Idera (IDRA) delivered earnings and revenue surprises of 17.86% and -93.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Idera Pharmaceuticals (IDRA) Q3 Earnings Preview: What to Expect

by Zacks Equity Research

Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session

by Zacks Equity Research

vTv Therapeutics (VTVT) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Idera Pharmaceuticals (IDRA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Idera (IDRA) delivered earnings and revenue surprises of 26.25% and -9.44%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

    by Zacks Equity Research

    Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.

      Idera Stock Down, Study on Dermatomyositis Candidate Fails

      by Zacks Equity Research

      Shares of Idera (IDRA) decline following the failure of a phase II study of its pipeline candidate, IMO-8400, on adult patients with dermatomyositis.

        Options Traders Expect Huge Moves in Idera Pharmaceuticals (IDRA) Stock

        by Zacks Equity Research

        Investors in Idera Pharmaceuticals (IDRA) need to pay close attention to the stock based on moves in the options market lately.

          BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall

          by Zacks Equity Research

          Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.

            Is the Options Market Predicting a Spike in Idera (IDRA) Stock?

            by Zacks Equity Research

            Investors in Idera (IDRA) need to pay close attention to the stock based on moves in the options market lately.

              Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4%

              by Zacks Equity Research

              Idera Pharmaceuticals (IDRA) shares rose more than 14% in the last trading session, amid huge volumes.

                Idera Pharmaceuticals (IDRA) Looks Good: Stock Up 13.3%

                by Zacks Equity Research

                Idera Pharmaceuticals, Inc. (IDRA) shares rose over 13% in the last trading session.